Manuscripts
Showing 1543 manuscripts.
The role of cognitive functioning in medication adherence of children and adolescents with HIV infection.
Citation
Kathleen Malee, Paige L. Williams, Grace Montepiedra, Sharon L. Nichols, Patricia Sirois, Deborah S. Storm, John J. Farley, Betsy Kammerer. The role of cognitive functioning in medication adherence of children and adolescents with HIV infection.. Journal of Pediatric Psychology. 2009. 34: 165-75. PMID: 18647794Year
2009
Journal
Journal of Pediatric Psychology
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
Citation
Christina M. Marra, Yu Zhao, David B. Clifford, Scott L. Letendre, Scott Evans, Kate Henry, Ronald J. Ellis, Benigno Rodriguez, Robert W. Coombs, Giovanni Schifitto, Justin C. McArthur, Kevin R. Robertson. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009. 23: 1359-66. PMID: 19424052Year
2009
Journal
AIDS
Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.
Citation
Philip Keiser, David Alain Wohl, Michelle A. Kendall, Janet Andersen, Clyde S. Crumpacker, Stephen A. Spector, Judith Feinberg, Beverly L. Alston-Smith, Susan Owens, Suzette A. Chafey, Michael Marco, Sharon D. Maxwell-Henkel, Nell Lurain, Douglas Jabs, Constance A. Benson. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030.. HIV Clinical Trials. 2009. 10: 143-52. PMID: 19632953Year
2009
Journal
HIV Clinical Trials
Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)
Citation
David B. Clifford, Scott Evans, Yijun Yang, Edward P. Acosta, Heather Ribaudo, Roy (Trip) Gulick. Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clinical Trials. 2009. 10: 343-55.Year
2009
Journal
HIV Clinical Trials
Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients
Citation
David B. Clifford, Marlene Smurzynski, Lesley Suejean Park, Tzu-min Yeh, Yu Zhao, Laura L. Blair, Max Arens, Scott Evans. Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology. 2009. 73: 309-14. PMID: 19636051Year
2009
Journal
Neurology
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection
Citation
Susan Moir, Angelina Malaspina, Irini Sereti, Michel Morre, Richard Dunham, Renaud Buffet, John Spritzler, Guido Silvestri, Evgenia Aga, Michael M. Lederman, Michael Proschan, Kathleen A. Medvik, Cathy Battaglia, Alan Landay, Savita G. Pahwa, Margaret A. Fischl, David M. Asmuth, Allan R. Tenorio, John Altman, Lawrence Fox. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood. 2009. 113: 6304-14.Year
2009
Journal
Blood
A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients
Citation
Lisa M. Demeter, Hongyu Jiang, Lisa Mukherjee, Gene D. Morse, Robin DiFrancesco, Robert DiCenzo, Carrie Dykes, Prakash Sista, Lee Bacheler, Karin L. Klingman, Alex R. Rinehart, Mary Albrecht. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS. 2009. 23: 357-68.Year
2009
Journal
AIDS
Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection
Citation
Justin C. McArthur, Victor G. Valcour, Tzu-min Yeh, Russell Bartt, David B. Clifford, Mariana Gerschenson, Scott Evans, Bruce A. Cohen, G. J. Ebenezer, Peter Hauer, Linda L. Millar, Mary Gould, Paul T. Tran, Cecilia M. Shikuma, Scott Souza. Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection. HIV Medicine. 2009. 10: 103-110.Year
2009
Journal
HIV Medicine
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.
Citation
David W. Haas, Susan L. Koletar, Laura J. Laughlin, Michelle A. Kendall, Carol Suckow, John G. Gerber, Andrew R. Zolopa, Richard J. Bertz, Michael J. Child, Lara A. Hosey, Beverly L. Alston-Smith, Edward P. Acosta. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.. Journal of Acquired Immune Deficiency Syndromes. 2009. 50: 290-3. PMID: 19194314Year
2009
Journal
Journal of Acquired Immune Deficiency Syndromes
Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects
Citation
Samir K. Gupta, Lauren Komarow, Roy (Trip) Gulick, Richard B. Pollard, Gregory K. Robbins, Nora Franceschini, Lynda Anne Szczech, Susan L. Koletar, Robert C Kalayjian. Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. Journal of Infectious Diseases. 2009. 200: 614-8.Year
2009
Journal
Journal of Infectious Diseases